A medication that stops Alzheimer's in its tracks?

Share this article:

Baxter BioScience's Gammagard halted the progression of Alzheimer's disease for as long as three years in a 16-patient trial. Results were presented at the Alzheimer's Association's annual meeting in Vancouver. The findings offer a “tantalizing” glimpse of the drug's potential, said William Thies, the association's chief medical and scientific officer.

A definitive study of 390 patients will be completed this year and released in early 2013, said Norman Relkin, the lead researcher, and the director of the Memory Disorders Program and a neurologist at New York Presbyterian/Weill Cornell Medical Center.

Share this article:
close

Next Article in Products

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the Prevantics® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.